Westat

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Westat sits in the top decile of US sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count).

13 total trials 2 currently recruiting 6 completed early-phase tilt top decile by trial count

Westat: 13 sponsored US clinical trials, 2 recruiting.

Westat sponsors 13 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting, and 6 completed. 2 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is HIV, with 2 trials.

Top-decile sponsor footprint

Westat ranks in the top decile of sponsors by registered trial count (#1,049 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Phase Distribution

PhaseTrial count
Phase 1 3
Phase 2 1
Phase 4 2

What is open in the Westat pipeline

2 recruiting of 13 indexed (15% open); 6 completed (46%).

Phase mix: 2 late (III/IV) vs 4 early (I/II) (early-phase heavy).

Top condition: HIV (2 trials), 5 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Westat: open-pipeline peers nationwide

Peers matched on 13 registered trials and 15% open enrollment, not the therapeutic-area sidebar.

Westat sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 12.912.91313.1 0%5%10%15%20% Total trials Recruiting share WestatAdaptimmuneAgennixAkili Interactive LabsAlumisArrowhead Regional Medical CenterAurinia PharmaceuticalsBronx VA Medical CenterCandel Therapeutics
Westat sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Westat sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 13 trials (± recruiting share)

Sponsors near 15% open enrollment (± trial volume)

What to do with this Westat page

13 registered trials is a research-attention snapshot, not an endorsement of Westat or any single study.

  • 2 of Westat's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • HIV is the condition Westat studies most, compare against other sponsors active in the same condition before evaluating a specific study. See HIV trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Westat pipeline card: 13 registered trials from official public datasets.Report a data error.